심뇌혈관질환 예방을 위한 아스피린의 근거중심 사용법

키워드

참고문헌 (80)

1. Park KA, "Statistical analytic data of mortality & causes of deaths" (2008), Korea National Statistical Office
2. Blaha MJ, "A practical "ABCDE" approach to the metabolic syndrome", Mayo Clin Proc, 83, pp.932~941 (2008)
3. Korea Centers for Disease Control and Prevention, "The healthy lifestyle for prevention of cardio cerebrovascular diseases-nine preventive rules: Joint announcement of the Government and the Institute" (2008), Korea Centers for Disease Control and Prevention
4. Reaven GM, "Banting Lecture 1988. Role of insulin resistance in human disease. 1988", Nutrition, 13, pp.65~ (1997)
5. Wilson PW, "Prediction of coronary heart disease using risk factor categories", Circulation, 97, pp.1837~1847 (1998)
6. Asia Pacific Cohort Studies Collaboration, "Cardiovascular risk prediction tools for populations in Asia", J Epidemiol Community Health, 61, pp.115~121 (2007)
7. Vane JR, "The mechanism of action of aspirin", Thromb Res, 110, pp.255~258 (2003)
8. "Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients", BMJ, 308, pp.81~106 (1994), Antiplatelet Trialists' Collaboration
9. 임정윤, "건강 검진자에서의 Helicobacter pylori 혈청학적 유병률", 대한내과학회지, 70(6), pp.636~642 (2006), 대한내과학회
10. Hyun-Seok Park, "Recent Epidemiological Trends of Stroke", 대한신경외과학회지, 43(1), pp.16~20 (2008), 대한신경외과학회
11. Gasparyan AY, "The role of aspirin in cardiovascular prevention: implications of aspirin resistance", J Am Coll Cardiol, 51, pp.1829~1843 (2008)
12. FitzGerald GA, "Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists", Am J Cardiol, 68, pp.11B~15B (1991)
13. Patrono C, "Clinical pharmacology of platelet cyclooxygenase inhibition", Circulation, 72, pp.1177~1184 (1985)
14. Bhatt DL, "ACCF", ACG, Circulation, pp.2008, 118[DOI]
15. Fauci AS, "principles of internal medicine. 17th ed" (2008), McGraw-Hill Medical
16. "Final report on the aspirin component of the ongoing Physicians' Health Study", N Engl J Med, 321, pp.129~135 (1989), Steering Committee of the Physicians' Health Study Research Group
17. Mosca L, "chemoprevention: one size does not fit all", Circulation, 117, pp.2844~2846 (2008)
18. Kikano GE, "Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician", Mayo Clin Proc, pp.583~593 (2007)
19. Becker RC, "The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", Chest, 133(6), pp.S776~S814 (2008)
20. Adams RJ, "Update to the AHA", ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic att ack, 2008, pp.39, 1647~1652
21. Sobel M, "American College of Chest Physicians; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", Chest, 133(6), pp.S815~S843 (2008)
22. Peto R, "Randomised trial of prophylactic daily aspirin in British male doctors", Br Med J (Clin Res Ed), 296, pp.313~316 (1988)
23. "Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework", Lancet, 351, pp.233~241 (1998)
24. Hansson L, "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial", Lancet, 351, pp.1755~1762 (1998), HOT Study Group
25. de Gaetano G, "Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project", Lancet, 357, pp.89~95 (2001)
26. Eidelman RS, "An update on aspirin in the primary prevention of cardiovascular disease", Arch Intern Med, 163, pp.2006~2010 (2003)
27. Ridker PM, "A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women", N Engl J Med, 352, pp.1293~1304 (2005)
28. Berger JS, "Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials", JAMA, 295, pp.306~313 (2006)
29. Greving JP, "Cost-eff ectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk", Circulation, 117, pp.2875~2883 (2008)
30. Feigin VL, "Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century", Lancet Neurol, 2, pp.43~53 (2003)
31. "Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group", Lancet, 352, pp.1801~1807 (1998)
32. Ueda K, "Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors", Stroke, 19, pp.48~52 (1988)
33. Iso H, "Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial", N Engl J Med, 320, pp.904~910 (1989)
34. "Epidemiology of cerebrovascular disease in Korea-a Collaborative Study", J Korean Med Sci, 8, pp.281~289 (1993), Korean Neurological Association
35. De Backer G, "European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)", Eur J Cardiovasc Prev Rehabil, 10, pp.S1~S10 (2003)
36. Morimoto T, "Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan", Am J Med, 117, pp.459~468 (2004)
37. Ahn KA, "Framingham equation model overestimates risk of ischemic heart disease in Korean men and women", Korean J Epidemiol, 28, pp.162~170 (2006)
38. Hayden M, "Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force", Ann Intern Med, 136, pp.161~172 (2002)
39. Scheiman JM, "NSAIDs, gastrointestinal injury, and cytoprotection", Gastroenterol Clin North Am, 25, pp.279~298 (1996)
40. van Oijen MG, "Peptic ulcerations are related to systemic rather than local eff ects of low-dose aspirin", Clin Gastroenterol Hepatol, 6, pp.309~313 (2008)
41. Lanza FL, "A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology", Am J Gastroenterol, 93, pp.2037~2046 (1998)
42. Donnelly MT, "Low-dose misoprostol for the prevention of lowdose aspirin-induced gastroduodenal injury", Aliment Pharmacol Ther, 14, pp.529~534 (2000)
43. Goldstein JL, "Ulcer recurrence in high-risk patients receiving nonsteroidalantiinfl ammatory drugs plus low-dose aspirin: results of a post HOC subanalysis", Clin Ther, 26, pp.1637~1643 (2004)
44. Silverstein FE, "Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, doubleblind, placebo-controlled trial", Ann Intern Med, 123, pp.241~249 (1995)
45. Lanas A, "Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal antiinfl ammatory drugs, antiplatelet agents, and anticoagulants", Am J Gastroenterol, 102, pp.507~515 (2007)
46. Scheiman JM, "Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors", Am J Gastroenterol, 101, pp.701~710 (2006)
47. Pilotto A, "Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin", non-steroidal anti-infl ammatory drugs, 2004, pp.20, 1091~1097
48. 김정욱, "비스테로이드소염제 유발 위창자병증", 대한소화기학회지, 52(3), pp.134~141 (2008), 대한소화기학회
49. Yeomans ND, "Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin", Aliment Pharmacol Ther, 22, pp.795~801 (2005)
50. Lanas A, "Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin", Aliment Pharmacol Ther, 16, pp.779~786 (2002)
51. Stack WA, "Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding", Aliment Pharmacol Ther, 16, pp.497~506 (2002)
52. Lai KC, "Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use", N Engl J Med, 346, pp.2033~2038 (2002)
53. Chan FK, "Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking lowdose aspirin or naproxen", N Engl J Med, 344, pp.967~973 (2001)
54. American Gastroenterological Association, "Consensus development conference on the use of nonsteroidal anti-infl ammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin", Clin Gastroenterol Hepatol, 4, pp.1082~1089 (2006)
55. 정현채, "Helicobacter pylori 양성인 소화성 궤양 환자에서 Clarithromycin을 포함한 단일 삼제요법 후의 재감염률과 임상상", 대한소화기학회지, 39(2), pp.93~100 (2002), 대한소화기학회
56. 김천태, "4년간의 추적조사에 의한 농촌지역 주민의 Helicobacter pylori 재감염률과 관련요인", 대한소화기학회지, 46(1), pp.39~47 (2005), 대한소화기학회
57. Ogawa H, "Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial", JAMA, 300, pp.2134~2141 (2008)
58. Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines", Circulation, 110, pp.227~239 (2004)
59. Bartolucci AA, "Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin", Am J Cardiol, 98, pp.746~750 (2006)
60. Mazzone T, "Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies", Lancet, 371, pp.1800~1809 (2008)
61. Otsuki M, "Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients", Diabetes, 46, pp.2096~2101 (1997)
62. Albertini JP, "Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: eff ect of intensive insulin treatment", Diabetes Care, 21, pp.1008~1013 (1998)
63. Davi G, "Determinants of F2-isoprostane biosynthesis and inhibition in man", Chem Phys Lipids, 128, pp.149~163 (2004)
64. Snoep JD, "Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis", Arch Intern Med, 167, pp.1593~1599 (2007)
65. Krasopoulos G, "Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis", BMJ, 336, pp.195~198 (2008)
66. Tantry US, "Resistance to antiplatelet drugs: current status and future research", Expert Opin Pharmacother, 6, pp.2027~2045 (2005)
67. Hankey GJ, "Aspirin resistance", Lancet, 367, pp.606~617 (2006)
68. 이영경, "한국의 한 대학병원 환자에서의 아스피린 저항성의 빈도", The Korean Journal of Laboratory Medicine, 28(4), pp.251~257 (2008), 대한진단검사의학회
69. Catella-Lawson F, "Cyclooxygenase inhibitors and the antiplatelet eff ects of aspirin", N Engl J Med, 345, pp.1809~1817 (2001)
70. MacDonald TM, "Effect of ibuprofen on cardioprotective eff ect of aspirin", Lancet, 361, pp.573~574 (2003)
71. Gladding PA, "Th antiplatelet eff ect of six non-steroidal anti-infl ammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers", Am J Cardiol, 101, pp.1060~1063 (2008)
72. Strand V, "Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?", Lancet, 370, pp.2138~2151 (2007)
73. Jones R, "Gastrointestinal and cardiovascular risks of nonsteroidal anti-infl ammatory drugs", Am J Med, 121, pp.464~474 (2008)
74. Ferrario CM, "Role of the renin-angiotensinaldosterone system and proinflammatory mediators in cardiovascular disease", Am J Cardiol, 98, pp.121~128 (2006)
75. Flather MD, "Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients", Lancet, 355, pp.1575~1581 (2000), ACE-Inhibitor Myocardial Infarction Collaborative Group
76. Yusuf S, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342, pp.145~153 (2000)
77. Fox KM, "EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)", Lancet, 362, pp.782~788 (2003)
78. Meune C, "Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance", J Renin Angiotensin Aldosterone Syst, 4, pp.149~154 (2003)
79. Brunner-La Rocca HP, "Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy fi nally resolved?", Chest, 124, pp.1192~1194 (2003)
80. Aumegeat V, "Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors", Chest, 124, pp.1250~1258 (2003)

관련 논문AI추천